THE COMMUNITY ONCOLOGY ALLIANCE appointed new officers. Bruce Gould, of Northwest Georgia Oncology Centers in Marietta, Ga., was named president of COA.
JOHN CLEVELAND was named associate center director of basic science at Moffitt Cancer Center.
CORNELIA ULRICH and BRUCE EDGAR will join the Huntsman Cancer Institute at the University of Utah as early as Sept. 1.
JAMES DOWNING was named CEO of St. Jude Children's Research Hospital, effective July 15. Downing most recently has served as deputy director, executive vice president and scientific director of the hospital.
THOMAS HANSEN, chief executive officer of Seattle Children's, will retire in 2015 as part of a long-planned leadership transition.
LYNDA CHIN was named a recipient of the Chancellor's Health Fellowship by MD Anderson Cancer Center.
BAYER PHARMA AG and arGEN-X announced a collaboration to develop therapeutic antibodies.
ELI LILLY AND COMPANY and Qiagen N.V. announced a plan to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.
DANA-FARBER CANCER INSTITUTE and Trovagene Inc. entered into a clinical collaboration to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
YESHIVA UNIVERSITY and Montefiore Health System agreed to have Montefiore assume greater responsibility for the day-to-day operations and financial management of Albert Einstein College of Medicine, with Yeshiva remaining the degree-granting institution.
